Full Text View
Tabular View
No Study Results Posted
Related Studies
Phase II Trial of Thalidomide Combined With Concurrent Chemoradiotherapy in Esophageal Cancer
This study is currently recruiting participants.
Verified February 2012 by Changzhou No.2 People's Hospital
Study NCT01551641   Information provided by Changzhou No.2 People's Hospital

First Received on February 24, 2012.   Last Updated on March 12, 2012   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Esophageal Cancer
Additional conditions recognized in this trial
Esophageal Diseases
Esophageal Neoplasms
More general conditions related to this trial
Digestive System Diseases
Digestive System Neoplasms
Gastrointestinal Diseases
Gastrointestinal Neoplasms
Head and Neck Neoplasms
Neoplasms
Neoplasms by Site
Interventions listed in this trial
chemoradiotherapy
thalidomide
without thalidomide
More general drug interventions related to this trial
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Anti-Bacterial Agents
Anti-Infective Agents
Antineoplastic Agents
Growth Inhibitors
Growth Substances
Immunologic Factors
Immunosuppressive Agents
Leprostatic Agents
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
Changzhou No.2 People's Hospital


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services